Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest
On 14 November 2025, Precigen, Inc. (NASDAQ: PGEN) is back in the spotlight. The gene‑therapy specialist’s stock is trading roughly 25–30% higher intraday around $4.90–$5.00, after closing at $3.86 on 13 November, on surging volume of nearly 11 million shares.StockAnalysis+1 The move caps a spectacular 12‑month run in which the stock has delivered well over 300% total return, powered by full FDA approval and U.S. launch of its PAPZIMEOS™ (zopapogene imadenovec‑drba) therapy for recurrent respiratory papillomatosis (RRP) and a wave of bullish post‑earnings commentary.Simply Wall St+1 Below is a breakdown of all the key Precigen news and market developments relevant
